SAN DIEGO--Industrial genomics company Sequenom announced last week that it reached a collaborative and a commercial agreement with Methexis Genomics of Ghent, Belgium. The companies intend to use their combined technologies to quickly and accurately discover and assess genetic variations, including single-nucleotide polymorphisms in targeted regions of human and plant genomes, and to create and sell commercial products and services utilizing their combined technologies. Methexis has also purchased Sequenom's MassArray system as a platform for its differential sequencing technology for the discovery of genetic variations, such as SNPs.
Hubert Koster, Sequenom's president and CEO said that using Methexis' SNP discovery technology with the mass array system for SNP analysis would create the potential to scan genes for genetic variation with greater speed and accuracy. "This combined with Sequenom's automated SNP assay design and validation capabilities, we believe will lead to highly valuable genomic products that combine discovery, function, and validation of genetic information associated with specific diseases," said Koster.
Methexis Genomics was founded in 1998 to capitalize on the demand to discover genetic variations in viral, bacterial, human, and plant genomes. Methexis' technology is based on a proprietary innovative concept for diagnostic sequencing using mass spectrometry.